Abstract:Background: The activation of the NLRP3 inflammasome has recently been revealed as a novel pathological mechanism of coronary heart disease (CHD). The Dan-Lou tablets (DLT) is widely used in the clinical treatment of CHD and prescription characterized by multi-component and multi-target regulation. However, the anti-inflammatory mechanism of DLT in the treatment of CHD remains unclear. Purpose: This study aimed to evaluate the effect of DLT in the treatment of CHD on the priming and activation of the NLRP3 inflammasome and to investigate the underlying anti-inflammatory mechanisms. Methods: First, CHD rats model were established by a high-fat diet combined with left anterior coronary artery ligation (LADCA) followed by DLT intervention. The therapeutic effect of DLT was evaluated according to cardiac function, lipid level, and cardiac histopathology. Next, data-independent acquisition (DIA) proteomics was used to identify the key differential proteins of DLT intervention in CHD rats, and bioinformatics analysis was performed. Finally, the differentially expressed proteins in the NOD-like signaling pathway were verified based on bioinformatics results, and the priming and activation steps of the NLRP3 inflammasome were detected. Results: In this study, a high-fat diet combined with LADCA was utilized to generate a CHD model, and DLT alleviated myocardial ischemia injury by inhibiting lipid deposition and inflammatory response. Proteomic studies observed that the RNF31, TXN2, and GBP2 of the NOD-like receptor signaling pathway were verified as the key targets of DLT in inhibiting myocardial injury in CHD rats. Furthermore, DLT in the treatment of CHD rats may function through the downregulation of P2X7R expression, thereby interfering with the priming (TLR4/MyD88/NF-κB) and activation (NLRP3/ASC/Caspase-1) of the NLRP3 inflammasome regulated by HSP90, and may then reduce the release of the IL-1β and IL-18 inflammatory factors to play an anti-myocardial injury effect. Conclusion: Our findings elucidate a novel mechanism of DLT and provide some new drug evaluation targets and therapeutic strategies for CHD. This study innovatively proposed that DLT further exerts an anti-myocardial injury effect by inhibiting P2X7R expression, thereby interfering with the priming (TLR4/MyD88/NF-κB) and activation (NLRP3/ASC/Caspase-1) of the NLRP3 inflammasome regulated by HSP90, and then downregulates the release of the IL-1β and IL-18 inflammatory factors.

Anti-Toll-like Receptor 2 Antibody Inhibits Nuclear Factor Kappa B Activation and Attenuates Cardiac Damage in High-Fat-feeding Rats

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Anti-toll-like Receptor 2 Antibody Ameliorates Hepatic Injury, Inflammation, Fibrosis and Steatosis in Obesity-Related Metabolic Disorder Rats Via Regulating MAPK and NF-κB Pathways.

Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice

Abstract 15583: Toll-Like Receptor 4 Knockout Preserves Cardiac Function in High Fat Diet-Induced Obesity

RTA 408 Ameliorates Diabetic Cardiomyopathy by Activating Nrf2 to Regulate Mitochondrial Fission and Fusion and Inhibiting NF-κB-mediated Inflammation.

Toll-like receptor 2 deficiency ameliorates obesity-induced cardiomyopathy via inhibiting NF-κB signaling pathway

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

TLR4 Knockout Attenuated High Fat Diet-Induced Cardiac Dysfunction Via NF-κB/JNK-dependent Activation of Autophagy.

Leukocyte Cell-Derived Chemotaxin 2 Inhibits Development of Atherosclerosis in Mice

Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2

PPAR-γ with Its Anti-Fibrotic Action Could Serve As an Effective Therapeutic Target in T-2 Toxin-Induced Cardiac Fibrosis of Rats.

TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells

Dan-Lou tablets reduce inflammatory response by inhibiting the activation of NLRP3 inflammasome for coronary heart disease

Toll-Like Receptor-2 in Cardiomyocytes and Macrophages Mediates Isoproterenol-Induced Cardiac Inflammation and Remodeling

Toll-like Receptor 4 Differentially Modulates Cardiac Function in Response to Chronic Exposure to High-Fat Diet and Pressure Overload.

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

Effects of N-3 Polyunsaturated Fatty Acid on the Expression of Toll-like Receptor2/4 in Chronic Heart Failure Rats

Regulation of TLR4 Expression Mediates the Attenuating Effect of Erythropoietin on Inflammation and Myocardial Fibrosis in Rat Heart

Toll-Like Receptor 2 Signaling Deficiency in Cardiac Cells Ameliorates Ang II-Induced Cardiac Inflammation and Remodeling

The Mechanism Underlying the Protective Effects of Tannic Acid Against Isoproterenol-Induced Myocardial Fibrosis in Mice